Sprint Bioscience AB's total assets for Q3 2025 were kr21.44M, a decrease of -44.46% from the previous quarter. SE:SPRINT total liabilities were kr15.37M for the fiscal quarter, a -36.71% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.